Tevogen gains after it reaffirms revenue forecast for experimental oncology drugs

ReutersApr 28, 2025 8:57 PM

Shares of drug developer Tevogen TVGN.O up 49.35% at $1.40 in after-market trading

Company reaffirms top-line revenue forecast for its experimental oncology drugs

Projects $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion

Stock down 9% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

April NFP Lands at 8:30 AM Today — 65K Forecast, a New Fed Chair, and the Dollar at Triple-Bottom Support

TradingKey - April 2026 NFP forecast 62K–70K vs March 178K. Unemployment expected 4.3%. Fed on hold at 3.50–3.75% with Kevin Warsh as new chair. DXY triple-bottom at $97.69. Trade setup inside.

US-Iran Tensions Heat Up Again, Brent Crude Prices Return Above $100

TradingKey - Oil prices surge as US-Iran clashes resume following a brief de-escalation.

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

TradingKey - During the US market opening session on May 7, Tesla (TSLA.US) shares extended their rebound momentum, rising more than 2% at one point to open at $406, returning above the $400 level. On May 5 and 6, the stock touched the $400 mark intraday but closed below that threshold on both days.

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

TradingKey - On Wednesday (May 7), Anthropic reached an agreement with Elon Musk's SpaceX to access SpaceX's massive data center 'Colossus 1.' Meanwhile, Musk announced that xAI would be dissolved as an independent company and renamed SpaceXAI, becoming an AI product line within SpaceX. Can SpaceX's

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

With a sold-out HBM pipeline, leadership in G9 NAND technology, and a valuation that has yet to fully account for its 2030 trillion-dollar potential, Micron remains a cornerstone "buy" for any long-term tech portfolio.

Featured Tools